Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase PHASE2
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A prospective randomized trial designed to evaluate the mean decrease in Ki67 after 4 weeks of elacestrant monotherapy and in combination with leuprorelin in patients with early-stage HR+ BC. This preoperative study will enroll consecutive patients with early stage HR+ BC who are not candidates for neoadjuvant chemotherapy but are eligible for short-term preoperative treatment with elacestrant, with or without leuprorelin, followed by breast surgery. A total of three dedicated Formalin-fixed paraffin embedded (FFPE) samples (mandatory for all patients), along with two frozen biopsy (only for participants at Gustave Roussy), are planned to be collected at the time of inclusion from the biopsy sample and from the surgical specimen. Blood samples will also be collected throughout the study.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Elacestrant — Patients will receive elacestrant 345 mg/daily administered orally for 4 weeks.
  • Drug: Leuprorelin — Patients randomized in arm B will recieve Leuprorelin at Day 1 and Day 29

Primary Outcomes

  • To determine if 4 weeks of elacestrant monotherapy determines a non-inferior anti-proliferative effect, measured by Ki67, in comparison to elacestrant with leuprorelin in premenopausal patients with ER-positive/HER2- operable invasive BC. (Surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-06
Completion: 2027-05-29
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Collaborators: Menarini Group
Contact Information
Study Contact:
Elie El Rassy, MD
+33 01 42 11 42 11
Elie.EL-RASSY@gustaveroussy.fr
Chloé Serhal, PhD
+33 01 42 11 42 11
Chloe.serhal@gustaveroussy.fr
Jean Zeghondy, MD
+ 33 01 42 11 42 11
Jean.ZEGHONDY@gustaveroussy.fr
Gustave Roussy
Interventions
  • Drug: Elacestrant — Patients will receive elacestrant 345 mg/daily administered orally for 4 weeks.
  • Drug: Leuprorelin — Patients randomized in arm B will recieve Leuprorelin at Day 1 and Day 29
Study Locations (1 sites)
Gustave Roussy, Villejuif, France
Eligibility Criteria
Inclusion Criteria: Each patient must meet all of the following inclusion criteria to be randomized in the study: 1. Aged 18 or more. 2. Signed Informed Consent Form prior to any study-specific procedure. Patients must be willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests and other study procedures. 3. Patients must be affiliated to a Social Security System (or equivalent). 4. Premenopausal women ensured by checking if the women were still having regular periods over the last 6 months without any hormonal treatment or hormonal contraception or if they were irregular, FSH and estradiol levels must fall within the premenopausal range according to local laboratory definition. 5. Histologically confirmed invasive breast carcinoma, confirmed by the local pathologist, ER-positive tumor cells ≥ 10% ER staining BC and HER2- according to ASCO criteria in immunohistochemistry (IHC) and/or genomic analysis (HER2 negativity is defined as IHC 0-1+, or \[IHC 2+ and in situ hybridization non-amplified\]), Ki67 index by local analysis of ≥ 10% and ≤ 30% on untreated tumor tissue. 6. Clinical stage I or II according to the eight edition of the American Joint Committee on Cancer, eligible for primary breast surgery. Note: Multifocal and multicentric tumors are permitted if they are considered clinical stage I or II according to Eight Edition of the AJCC. Biopsy of all lesions is not necessary and is left at the description of the investigator, but endocrine therapy response must be evaluated on the same tumor 7. Available pre-treatment tru-cut biopsy evaluable. 8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 14 days prior to the date of randomization. 9. Women of childbearing potential have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication. 10. Demonstrate adequate organ function within 7 days of inclusion : 1. Absolute neutrophil count ≥ 1.0 x 109/L 2. Platelet count ≥ 75 x 109/L 3. Hemoglobin ≥ 9.0 g/dL 4. Estimated glomerular filtration rate ≥30 mL/min/1.73 m² or creatinine clearance calculated by Cockcroft-Gault equation ≥ 30 mL/min Creatinine clearance ≥ 30 mL/min for subject with creatinine levels \> 1.5 x institutional upper limit of normal (ULN). 5. Alanine aminotransferase (ALT) ≤ 2.5x upper limit of normal (ULN). 6. Aspartate aminotransferase (AST) ≤ 3x ULN. 7. Total bilirubin ≤ ULN or total bilirubin ≤ 1.5x ULN with direct bilirubin ≤ ULN of the laboratory in subjects with documented Gilbert's Syndrome. 8. Potassium, sodium, calcium (corrected for albumin), magnesium, and phosphorus CTCAE v5.0 Grade ≤ 1. If Screening assessments are abnormal, chemistry assessments may be repeated up to 2 times; subjects may receive appropriate supplementation or treatment (eg, for hypercalcemia) prior to re-assessment. 9. International normalized ratio (INR) ≤ 1.5; subjects who are receiving anticoagulation treatment which is monitored by international normalized ratio (INR) (eg, warfarin) may be allowed to participate if they have a stable INR (ie, within therapeutic range) for at least 28 days prior to the first dose of study drug, in the absence of any exclusionary medical conditions, and provided that elacestrant would be appropriate therapy for the subject. 11. Women of childbearing potential must agree to use protocol-specified method(s) of contraception during trial treatments and for at least 120 days after the last dose of trial treatments. Highly effective contraception methods include: 1. Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 2. Placement of a non-hormonal intrauterine device. Exclusion Criteria: Patients who meet any of the following exclusion criteria will not be eligible for this study. 1. Patients non-candidate for upfront breast surgery or candidate for neoadjuvant chemotherapy. 2. Any systemic therapy (e.g, chemotherapy, targeted therapy, immune-therapy) or radiotherapy for current BC before study entry. 3. Prior treatment with LHRH-agonists over the last 6 months prior to the ICF signature. 4. Any active treatment for any cancer disease. 5. Any of the following within 6 months before enrollment: 1. Myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE v5.0 Grade ≥2, 2. Prolonged QTcF ≥ Grade 2 (ie, \> 480 msec), uncontrolled atrial fibrillation of any grade, coronary/peripheral artery bypass graft, heart failure ≥ Class II as defined by the New York Heart Association guidelines, 3. Cerebrovascular accident including transient ischemic attack 4. Child-Pugh Score greater than Class A, 5. Has a known hypersensitivity (≥ Grade 3) to the components of the study therapy or its analogs. 6. Coagulopathy or any history of coagulopathy within the past 6 months, including history of deep vein thrombosis or pulmonary embolism. However, subjects with the following conditions will be allowed to participate: 7. Adequately treated catheter-related venous thrombosis occurring \> 28 days prior to the first dose of study drug 6. Treatment with an anticoagulant, eg, warfarin or heparin, for a thrombotic event occurring \> 6 months before enrollmentenrolment, or for an otherwise stable and allowed medical condition (eg, well controlled atrial fibrillation), provided dose and coagulation parameters (as defined by local standard of care) are stable for at least 28 days prior to the first dose of study drug and provided that an AI would be an appropriate therapy for the subject. 7. Known difficulty in tolerating oral medications or conditions which would impair absorption of oral medications such as: uncontrolled nausea or vomiting (ie, CTCAE ≥ Grade 3 despite antiemetic therapy), ongoing gastrointestinal obstruction/motility disorder, malabsorption syndrome, or prior gastric bypass. 8. Unable or unwilling to avoid prescription medications, over-the-counter medications, dietary/herbal supplements (eg, St. John's wort), and/or foods (eg, grapefruit, pomelos, star fruit, Seville oranges and their juices) that are moderate/strong inhibitors or inducers of CYP3A4 activity. Participation will be allowed if the medication, supplements, and/or foods are discontinued for at least 5 half-lives or 14 days (whichever is longer) prior to study entry and for the duration of the study. 9. Pregnancy or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. 10. Any concurrent severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with compliance with study procedures or the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study. 11. Person deprived of their liberty or under protective custody or guardianship. 12. Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol. 13. Patients unwilling to or unable (as assessed by the investigator) to comply with the protocol.
Conditions Hepatic Artery Infusion, Liver Metastasi...
Phase PHASE2
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Study Objective: To Evaluate the Efficacy of Albumin-Bound Paclitaxel Combined with Nedaplatin via Hepatic Arterial Infusion as Later-Line Therapy for Breast Cancer Patients with Liver Metastases After Failure of Standard Treatment. Outcome Measures:Primary Outcome: Liver Progression-Free Survival (LPFS) Secondary Outcomes:Liver Objective Response Rate (LORR)、Progression-Free Survival (PFS) and Overall Survival (OS) Participants will: * Albumin-bound paclitaxel + nedaplatin (TP) regimen is administered via hepatic arterial infusion chemotherapy on Day 1 of each cycle. * Tumor response will be assessed every 6 weeks (±7 days) according to RECIST 1.1 criteria until disease progression is determined by the investigator.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Abraxane — Abraxane,200 mg,Via hepatic arterial catheter infusion,Every three weeks
  • Drug: Nedaplatin — Nedaplatin,100 mg,Via hepatic arterial catheter infusion,Every three weeks

Primary Outcomes

  • Liver progression-free survival, L-PFS (Up to approximately 33 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-02-01
Completion: 2028-01-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhejiang Cancer Hospital
Contact Information
Study Contact:
Xaolin Li
8615024437258
847678911@qq.com
Xiaolin Li
+86-571-88122222
847678911@qq.com
Zhejiang Cancer Hospital
Interventions
  • Drug: Abraxane — Abraxane,200 mg,Via hepatic arterial catheter infusion,Every three weeks
  • Drug: Nedaplatin — Nedaplatin,100 mg,Via hepatic arterial catheter infusion,Every three weeks
Study Locations (1 sites)
Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: * Patients with liver metastases from breast cancer pathologically confirmed via surgery or biopsy. * Advanced breast cancer patients with imaging-confirmed visceral tumor burden solely confined to liver metastases. * Patients who have previously failed at least two lines of standard therapy (including endocrine therapy, chemotherapy, or targeted therapy), or those for whom researchers determine that local therapy would yield greater benefit. * Age 18-70 years. * ECOG (Eastern Cooperative Oncology Group) performance status score of 0-2. • 0: Fully active, without any restrictions; • 1: Restricted in physically strenuous activity but ambulatory and able to carry out light work; • 2: Ambulatory and capable of all self-care but unable to carry out any work activities. * Liver function score (e.g., Child-Pugh) Class A-B. • Class A (5-6 points): Good hepatic reserve, well tolerated to surgery, low incidence of postoperative complications and mortality; • Class B (7-9 points): Moderately impaired hepatic reserve, poorly tolerated to surgery, increased postoperative complications and mortality; • Class C (≥10 points): Severely impaired hepatic reserve, very poorly tolerated to surgery, high risk of postoperative complications and mortality; surgery is generally not recommended. ⑦ Adequate organ function. • Hemoglobin ≥90 g/L, white blood cells ≥3.5×10⁹/L, neutrophils ≥1.5×10⁹/L, platelets ≥100×10⁹/L; • Serum creatinine ≤1.0×upper normal limit (UNL), and creatinine clearance \>60 mL/min; • Alanine aminotransferase (ALT) ≤1.5×UNL, aspartate aminotransferase (AST) ≤1.5×UNL, alkaline phosphatase (ALP) ≤1.5×UNL; • Total bilirubin (TBIL) ≤1.5×UNL; • No severe abnormalities on electrocardiogram, left ventricular ejection fraction (LVEF) ≥50%; • Absence of other severe medical conditions or comorbidities that would preclude tolerance to the clinical trial intervention. * Signed informed consent, indicating understanding of the trial's purpose, risks, and potential benefits. Exclusion Criteria: 1. History of other malignancies. 2. Breast and chest wall recurrence, brain metastases, multiple bone metastases with fracture risk, or visceral metastases outside the liver. 3. Tumor volume ≥70% of liver volume. 4. History of heart failure (NYHA class \>I), myocardial infarction, unstable angina, stroke, or poorly controlled arrhythmia. 5. Active infection, severe allergic reactions, or autoimmune diseases, including but not limited to: * Active tuberculosis (TB), currently receiving or having received anti-TB treatment within the past year; * HIV infection (HIV1/2 antibody positive); * Active hepatitis B or hepatitis C virus infection; * History of systemic lupus erythematosus, rheumatoid arthritis, chronic lymphocytic thyroiditis, hyperthyroidism, polyarteritis nodosa, autoimmune hemolytic anemia, etc. 6. Administration of live attenuated vaccines within 4 weeks prior to enrollment or planned during the study period. 7. Uncontrolled hypertension, diabetes, or other serious diseases. 8. Severe uncontrolled dysfunction of the liver, kidneys, lungs, or other vital organs. 9. Pregnant or lactating patients. 10. History of mental illness. 11. Known allergy to albumin-bound paclitaxel, nedaplatin, or related drugs. 12. Current participation in another clinical trial.
Conditions Breast Cancer Stage I, Breast Cancer Sta...
Phase NA
Enrollment 24
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: TheraBionic P1 Device — Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day and in the evening prior to surgical resection of early stage breast cancer.

Primary Outcomes

  • Pathological Response to Treatment (At time of surgery (after approximately 2 weeks of treatment and tumor resection))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-10
Completion: 2028-06-30
Eligibility
Age: 22 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Barbara Ann Karmanos Cancer Institute
Principal Investigators:
  • Lubina Arjyal, M.D. (PRINCIPAL_INVESTIGATOR) - Wayne State University
Contact Information
Study Contact:
Lubina Arjyal, M.D.
1-800-karmanos
arjyall@karmanos.org
248-922-6650
Karmanos Cancer Institute at McLaren Clarkston
Lubina Arjyal, MD
1-800-527-6266
arjyall@karmanos.org
Karmanos Cancer Institute
Interventions
  • Device: TheraBionic P1 Device — Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day and in the evening prior to surgical resection of early stage breast cancer.
Study Locations (8 sites)
Karmanos Cancer Institute at McLaren Clarkston, Clarkston, Michigan 48346 United States
Karmanos Cancer Institute, Detroit, Michigan 48201 United States
Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan 48334 United States
Karmanos Cancer Institute at McLaren Flint, Flint, Michigan 48532 United States
Karmanos Cancer Institute at McLaren Greater Lansing, Lansing, Michigan 48910 United States
Karmanos Cancer Institute at McLaren Lapeer Region, Lapeer, Michigan 48466 United States
Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey, Michigan 49770 United States
Karmanos Cancer Institute at McLaren Port Huron, Port Huron, Michigan 48060 United States
Eligibility Criteria
Inclusion Criteria: * Participant must have histologically proven invasive breast cancer that is HR (hormone receptor) positive and HER2 (Human Epidermal Growth Factor Receptor 2) negative according to the 2010 American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (ER and/or PR (progesterone receptor) \>1% and HER2 negative by immunohistochemistry \[IHC\] and/or fluorescent in situ hybridization \[FISH\]). * Participant must have early-stage operable disease (stage I-II or III who have planned upfront surgery) and agree to definitive upfront surgery. * Participant must be available for at least two weeks of TheraBionic treatment prior to scheduled resection * Participant must have archival tissue available. * Participant must be a woman aged 22 years or older * Participant must be able to understand a written informed consent document and be willing to sign it * Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * It is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, women of child-bearing potential must agree to avoid becoming pregnant starting at initiation of treatment up until at least 30 days after the last TheraBionic P1 session Exclusion Criteria: * Participants that are receiving or will receive neoadjuvant chemotherapy or neoadjuvant hormonal therapy * Participants with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints * Participants that are taking any other investigational drugs * Participants that are pregnant or breastfeeding due to the unknown but potential risk for adverse events. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued * Participants with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of TheraBionic P1 device (for example: mucositis, thrush, bleeding mucosal lesions, oral herpes, aphthous stomatitis, mouth ulcers, chancre sores, gingivostomatitis, herpangina, aphthae). * Participants receiving calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels (for example: amlodipine, nifedipine, ethosuximide, ascorbic acid/vitamin C, etc.) unless their medical treatment is discontinued at least one day prior to treatment. Participant must agree to abstain from using calcium channel blockers for the duration of treatment on study. * Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device * Participants with a known severe (e.g., anaphylactic) allergy to nickel.
Conditions Major Depressive Disorder (MDD)
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The orbitofrontal cortex (OFC), a region involved in emotional regulation, decision making, and reward processing, is a key area linked to antidepressant response. This study tests whether noninvasive stimulation of the OFC using transcranial magnetic stimulation (TMS) can improve depressive symptoms. TMS uses magnetic fields generated by a coil placed next to the scalp to alter brain activity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Sham TMS — The MagVenture MagPro system's active/sham coil (e.g., Cool-B65 A/P) will be used to deliver either active or sham TMS. The sham mode reproduces the same clicking sound and scalp sensation as active stimulation but does not induce cortical activation. The built-in MagPro double-blind feature ensures operator, participant, and investigator blinding. All participants will be randomized to receive active or sham TMS to the OFC in the first phase.
  • Device: Active TMS — TMS uses magnetic fields generated by a coil placed next to the scalp to alter brain activity at a specific region (i.e., OFC) protocol. Here, active TMS protocol is continuous intermittent theta burst stimulation (cTBS, a type of inhibitory TMS) to the right OFC. Investigators will use the MagVenture MagPro system's active/sham coil (e.g., Cool-B65 A/P) to deliver either active or sham TMS. All participants will be randomized to receive active or sham TMS to the OFC in the first phase. In the second phase, all participants will receive active TMS to the OFC. The active protocol to the right OFC is: continuous intermittent theta burst stimulation (cTBS, a type of inhibitory TMS).

Primary Outcomes

  • Beck Depression Inventory II (BDI-II) (The survey will be administered at 4 timepoints: Day 1 (baseline) and Day 10 (last day) of randomized phase; Day 1 (baseline) and Day 10 (last day) of open-label phase.)
  • Hamilton Depression Rating Scale (HDRS) - 24 item version (The survey will be administered at 4 timepoints: Day 1 (baseline) and Day 10 (last day) of randomized phase; Day 1 (baseline) and Day 10 (last day) of open-label phase.)
  • Rumination Response Scale (RRS) (The survey will be administered at 4 timepoints: Day 1 (baseline) and Day 10 (last day) of randomized phase; Day 1 (baseline) and Day 10 (last day) of open-label phase.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-15
Completion: 2030-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Subha Subramanian
Contact Information
Study Contact:
Subha Subramanian, MD
6176675247
ssubram5@bidmc.harvard.edu
Subha Subramanian, MD
ssubram5@bidmc.harvard.edu
Beth Israel Deaconess Medical Center
Interventions
  • Device: Sham TMS — The MagVenture MagPro system's active/sham coil (e.g., Cool-B65 A/P) will be used to deliver either active or sham TMS. The sham mode reproduces the same clicking sound and scalp sensation as active stimulation but does not induce cortical activation. The built-in MagPro double-blind feature ensures operator, participant, and investigator blinding. All participants will be randomized to receive active or sham TMS to the OFC in the first phase.
  • Device: Active TMS — TMS uses magnetic fields generated by a coil placed next to the scalp to alter brain activity at a specific region (i.e., OFC) protocol. Here, active TMS protocol is continuous intermittent theta burst stimulation (cTBS, a type of inhibitory TMS) to the right OFC. Investigators will use the MagVenture MagPro system's active/sham coil (e.g., Cool-B65 A/P) to deliver either active or sham TMS. All participants will be randomized to receive active or sham TMS to the OFC in the first phase. In the second phase, all participants will receive active TMS to the OFC. The active protocol to the right OFC is: continuous intermittent theta burst stimulation (cTBS, a type of inhibitory TMS).
Study Locations (1 sites)
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-65 years * Must be able to read, speak and understand English * DSM-5 diagnosis of major depressive disorder, experiencing a moderate to severe depressive episode (Hamilton Depression Rating Scale score greater than or equal to 17 points) * Must be judged by study staff to be capable of completing the study procedures * Participants will be in stable outpatient treatment with no recent (within the past 30 days) hospitalizations or changes in their medication regimens Exclusion Criteria: * DSM-5 moderate to severe substance use disorder within the past three months, based on Structured Clinical Interview for DSM-5 * Conditions that might result in increased risks of side effects or complications from rTMS or MRI, including: * History of fainting spells of unknown or undetermined etiology that might constitute seizures * Diagnosis of epilepsy with the exception of a single seizure of benign etiology (e.g., febrile seizures) in the judgment of a board-certified neurologist * Current or past history of a neurological disorder, such as stroke, a progressive neurologic disease, or intracranial brain lesion(s); and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment * Any unstable medical condition * Any metal in the brain or skull (excluding dental fillings) unless cleared by the responsible covering MD * Any devices which could be affected by TMS or MRI such as a pacemaker, medication pump, nerve stimulator, cochlear implant, TENS unit, ventriculo-peritoneal shunt unless cleared by the responsible covering MD * Pregnancy; All female participants will be required to have a pregnancy test; any participant who is pregnant will not be enrolled in the study. The pregnancy test will be administered by study staff trained to administer point of care pregnancy testing that complies with institutional laboratory policies
Conditions Cardiotoxicity, DPP3, HSCT, Allogeneic H...
Phase Not Applicable
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year. Conditioning and maintenance regimens carry a risk of both short- and long-term cardiotoxicity, leading to serious cardiovascular events including acute coronary syndrome (ACS), cardiac dysfunction, arrhythmias, pulmonary hypertension, and pericardial effusion. The pathophysiology of cardiotoxicity in HSCT patients remains poorly understood. It is therefore crucial to investigate underlying mechanisms and identify predictive factors of cardiotoxicity in order to provide appropriate cardiological follow-up and management. Current European Society of Cardiology guidelines recommend routine monitoring of HSCT patients with echocardiography and cardiac biomarkers (NT-proBNP, troponin), although these recommendations are based on small-scale studies. The cardiodepressor factor DPP3 has shown promising results in cardio-oncology, with a causal role in anthracycline-induced cardiac dysfunction. Its role in HSCT-related cardiotoxicity requires further evaluation. This multicenter study of HSCT recipients will be a valuable resource, enabling a better understanding of the pathophysiology of cardiotoxicity and prognosis. It will highlight imaging (echocardiography, calcium score, supra-aortic Doppler), electrocardiographic, and biological markers (including DPP3) associated with prognosis.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Composite cardiotoxicity outcome during follow-up of 1 year, defined as cardiovascular mortality, cardiac dysfunction, acute coronary syndrome, pericarditis, and supraventricular or ventricular arrhythmias. (During follow-up of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-25
Completion: 2028-12-25
Eligibility
Age: 15 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Collaborators: INSERM UMR-S 942 MASCOT, INSERM U1086 Cancers et Préventions, Fédération Française de Cardiologie
Contact Information
Study Contact:
Trecy Dr Gonçalves, Dr
+33142499162
trecy.goncalves@aphp.fr
Marie Robin, Pr
+33 1 42 49 47 60
marie.robin@aphp.fr
Saint Louis Hospital
Interventions
N/A
Study Locations (1 sites)
Saint Louis Hospital, Paris, 75010 France
Eligibility Criteria
Inclusion Criteria: * Age ≥ 15 years * Informed about the study and without objection to participation (or with consent from legal guardians) * Undergoing allogeneic HSCT Exclusion Criteria: * Patient not followed up at the participating center * Pregnant or breastfeeding women * Patient not affiliated with social security * Patient under guardianship, curatorship, or legal protection
Conditions Cancer, Insomnia, Pain, Depression Anxie...
Phase Not Applicable
Enrollment 260
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The diagnosis of cancer can be a major trigger for new sleep problems, especially insomnia, in people who did not have sleep issues before. Insomnia may appear early in the care pathway and can continue over time, often interacting with other physical or emotional symptoms. The main goal of this preliminary study is to describe how insomnia develops during the first months after a cancer diagnosis in patients who had no sleep problems at the time of diagnosis. This will be done through regular follow-up over time. A secondary aim is to identify the factors that may contribute to the onset or persistence of insomnia, such as the cancer treatments patients receive, as well as any medical or non-medical therapies used to manage sleep difficulties. The study will also look at whether patients who develop sleep problems are referred to psychologists trained in specific therapies for insomnia, and how well they follow and adhere to these treatments.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • The primary objective is to characterize the evolution, severity, and incidence of insomnia in patients newly diagnosed with cancer (over a 12-month period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-16
Completion: 2028-11-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 260 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Emile Roux
Contact Information
Study Contact:
Emilie GADEA, PhD
+33 471 043 538
science.writer@ch-lepuy.fr
Interventions
N/A
Study Locations (1 sites)
12 boulevard du Dr Chantemesse, Le Puy-en-Velay, 43000 France
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of metastatic or non-metastatic cancer, * Cancer treated with intravenous chemotherapy and/or immunotherapy administered intravenously or subcutaneously, * Age ≥ 18 years, * Ability to read and understand French, * Patient covered by a social security system, * Signed informed consent. Exclusion Criteria: * SCI questionnaire score \<16 * Diagnosed or controlled sleep disorders * Presence of severe cognitive disorders (e.g., Alzheimer's disease) or major psychiatric disorders (e.g., psychosis), as noted in the medical record, observed at recruitment, or reported by the patient * Patient in an emergency situation, or subject to a legal protection measure (guardianship, curatorship, or judicial protection) and unable to provide consent
Conditions Depression - Major Depressive Disorder
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this prospective clinical trial is to evaluate the effect that prosthetic replacement of the ocular surface ecosystem (PROSE, BostonSight, Needham MA) treatment may have on mental health, particularly affective mood disorders. Correlation between changes in mental health and ocular symptom improvement and/or visual function improvement will be evaluated.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Patient Health Questionnaire 9 (PHQ9) (At enrollment, 28 days post PROSE dispense and 84 days post PROSE dispense)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-11
Completion: 2029-10-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Boston Sight
Principal Investigators:
  • Daniel Brocks, MD (PRINCIPAL_INVESTIGATOR) - Boston Sight
Contact Information
Study Contact:
Estelle Crowley, BS
17817267506
ecrowley@bostonsight.org
Estelle Crowley, BS
7817267506
ecrowley@bostonsight.org
BostonSight
dbrocks@bostonsight.org
BostonSight
Interventions
N/A
Study Locations (1 sites)
BostonSight, Needham, Massachusetts 02494 United States
Eligibility Criteria
Inclusion Criteria: 1. Written Informed Consent has been obtained prior to any study-related procedures taking place. 2. Subject is Male or Female, 18 years of age or older prior to the initial visit. 3. Patient is proceeding with a PROSE or scleral lens consultation in one or both eyes for the primary diagnosis of ocular surface disease, including but not limited to Ocular Graft vs Host Disease, Keratoconjunctivitis Sicca, Dry eye, Sjogren's Disease, Rheumatologic ocular surface disease, Exposure Keratitis, Limbal Stem Cell Deficiency, Steven Johnson Syndrome, Mucous Membrane Pemphigoid (Ocular Cicatricial Pemphigoid), Atopic Keratoconjunctivitis, Chemical injury. 4. Baseline PHQ-9 score \> 4 5. Baseline OSDI score of 13 or greater 6. In the opinion of the investigator, the subject can follow study instructions, complete all study procedures and visits 7. Is able to understand the English language in verbal and written interactions - Exclusion Criteria: 1. Is currently participating in any other type of eye-related clinical research study that in the opinion of the investigator would interfere with the study 2. Is pregnant or nursing as reported by the subject. 3. Has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study. 4. Recently started medication or other therapeutic treatments for affective mood disorders (such as depression) within the last 8 weeks. 5. Recently started new treatment for ocular surface disease, including but not limited to topical medicated drops, procedures, punctal plugs within the last 8 weeks. 6. Ocular surgery within the last 8 weeks 7. Planned ocular surgery within the study period 8. Has a known allergy to topical ophthalmic sodium fluorescein dye 9. Has a known intolerance to topical ophthalmic normal saline 10. Neurotrophic Keratitis 11. Corneal ectasia 12. PROSE or scleral lens wearer within the last 1 year prior to Visit 1 \[subjects who have solely tried a PROSE or scleral lens in an office setting consultation (and were never dispensed for home use) ARE eligible for enrollment, regardless of whether it occurred in the last year\] 13. Is an employee of BostonSight or an employee of a site performing the study -
Conditions Breast Cancer
Phase Not Applicable
Enrollment 229
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: CDK4/6 inhibitor — abemaciclib OR ribociclib

Primary Outcomes

  • Invasive Disease-free Survival (iDFS) (From the date of surgery until time of event up to 2 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-08-28
Completion: 2033-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 229 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wenjin Yin
Principal Investigators:
  • Wenjin Yin, M.D. (PRINCIPAL_INVESTIGATOR) - Renji Hospital,School of Medicine, Shanghai Jiaotong University
Contact Information
Study Contact:
Wenjin Yin, M.D.
86(21)68385569
yinwenjin@renji.com
Wenjin Yin
86(21)68385569
yinwenjin@renji.com
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Interventions
  • Drug: CDK4/6 inhibitor — abemaciclib OR ribociclib
Study Locations (1 sites)
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127 China
Eligibility Criteria
Inclusion Criteria: * Aged ≥18 and older * Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence * HR+/HER2- * ECOG 0-3 * Subjects meeting current guideline recommendations and planning to receive adjuvant CDK4/6 inhibitors Exclusion Criteria: * During pregnancy or lactation * Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption
Conditions Heart Failure, Anthracycline-induced Car...
Phase PHASE2
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized, double-blind, placebo-controlled clinical trial is to determine whether dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, can help prevent anthracycline-induced cardiotoxicity caused by anthracycline chemotherapy in adult women with breast cancer receiving (neo)adjuvant treatment. The main questions the study aims to answer are: i) Does dapagliflozin reduce the decline in left ventricular function (measured by LVEF, GLS, and myocardial work) during and after anthracycline therapy? ii) Does dapagliflozin lessen the deteriorating effect of chemotherapy on endothelial function and arterial stiffness? iii) Does dapagliflozin effect levels of cardiac injury and inflammation biomarkers (e.g., hs-troponin T, NT-proBNP, ST-2, GDF-15, galectin-3, IL-6, MPO)? Researchers will compare dapagliflozin 10 mg daily with placebo to see whether those receiving dapagliflozin experience less heart and vascular impairment during treatment. Participants will: * Take either dapagliflozin or placebo once daily during anthracycline chemotherapy. * Undergo heart and vascular ultrasound, and a 6-minute walk test before chemotherapy and again at 24 and 52 weeks. * Provide blood samples before, during and after chemotherapy to measure cardiac biomarkers. * Complete multiple questionnaires on quality of life.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Dapagliflozin 10 mg — Forgixa® 10 mg daily
  • Drug: Placebo — Lactose tablet daily

Primary Outcomes

  • Change in Global Longitudinal Strain (GLS) (52 weeks)
  • Change in Flow-Mediated Dilation (FMD) of the Brachial Artery (52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-02-01
Completion: 2029-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Medical Centre Ljubljana
Contact Information
Study Contact:
Jure Tršan
Slovenia
jure.trsan@gmail.com
Jure Tršan
+3861 5228011
jure.trsan@kclj.si
University Medical Centre Ljubljana
Interventions
  • Drug: Dapagliflozin 10 mg — Forgixa® 10 mg daily
  • Drug: Placebo — Lactose tablet daily
Study Locations (1 sites)
University Medical Centre Ljubljana, Ljubljana, 1000 Slovenia
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years. * Histologically confirmed breast cancer with planned (neo)adjuvant anthracycline-based chemotherapy (4 cycles of epirubicin + cyclophosphamide or doxorubicin + cyclophosphamide). * Eligible to start dapagliflozin or placebo prior to or at initiation of chemotherapy. * Able to perform baseline echocardiography, vascular ultrasound (FMD and carotid stiffness), 6-minute walk test, and biomarker sampling. * Willing and able to provide written informed consent. Exclusion Criteria: * Known heart failure (any prior diagnosis of HF). * Clinically significant valvular heart disease. * Prior exposure to chemotherapy or radiotherapy to the left chest. * Type 1 diabetes mellitus. * Symptomatic hypotension. * History of recurrent urinary tract infections. * History of diabetic ketoacidosis or ketonemia. * Severe hepatic impairment (ALT, AST, ALP \>3× upper limit of normal). * Severe renal impairment (eGFR \<20 mL/min/1.73 m²). * Known allergy or intolerance to SGLT-2 inhibitors. * Any use of SGLT-2 inhibitor therapy within 3 months prior to enrollment. * Pregnancy or breastfeeding. * Any condition that, in the investigator's judgment, could interfere with study participation, safety, or completion.
Conditions Anxiety Depression
Phase NA
Enrollment 410
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled trial will evaluate the Norwegian adaptation of the Big Five intervention (Things You Do; TYD) for individuals with self-reported anxiety and/or depressive symptoms. The study will compare the Big Five intervention with a Gratitude intervention and a waitlist control. A total of 410 participants will be recruited online and randomized to one of three groups. Intervention groups will receive a brief module and daily SMS reminders (Monday-Friday for four weeks) encouraging engagement in either the five daily actions or gratitude practices. The primary aim is to replicate findings from the Australian trial by comparing TYD to a waitlist control. A secondary aim is to examine whether TYD yields better outcomes than the active Gratitude control. This study will provide evidence on the effectiveness and cross-cultural applicability of a low-cost, scalable intervention for improving mental health. Data from the study will also be used to evaluate the psychometric properties of the Norwegian translation of the Things You Do-15 instrument (TYD-15).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Big Five — The intervention is self-guided and consists of a brief 14-page psychoeducation module that they are introduced to in the beginning of a 4-week intervention period (day 0). The module starts with a general introduction to mental health and Things you do action and how it promotes mental health. The final section presents the five core actions: 1) healthy thinking, 2) meaningful activities, 3) goals and plans, 4) healthy habits, and 5) social connections. Participants are advised to engage in the five daily actions throughout the intervention period. They are also encouraged to fill out a weekly planner and monitor their progress by keeping an overview of the number of daily activities in "My Week".The participants receive the module on a Sunday (Day 0). They receive text reminders Monday to Friday for four weeks, encouraging them to engage in the actions.
  • Other: Gratitude — The intervention is self-guided and consists of a brief 14-page psychoeducation module that they are introduced to in the beginning of a 4-week intervention period (day 0). The module starts with a general introduction to mental health and Gratitude and how it promotes mental health, followed by a short summary on the benefits of gratitude. The final section introduces practical strategies for cultivating gratitude by focusing on five key gratitude activities: 1) keeping a gratitude journal, 2) expressing gratitude to others, 3) finding gratitude in misfortune or difficult situations, 4) appreciating good things and 5) another perspective. The participants receive the module on a Sunday (Day 0). They receive text reminders Monday to Friday for four weeks, encouraging them to engage in the actions.

Primary Outcomes

  • Generalized Anxiety Disorder- 7 (At Screening)
  • Patient Health Questionnaire - 2 (At pre, day 8, day 15, day 22, post, follow-up 3, 6, and 12 months)
  • Patient Health Questionnaire - 9 (At screening)
  • Generalized Anxiety Disorder - 2 (At pre, day 8, day 15, day 22, post, follow-up 3, 6, and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-10
Completion: 2027-09-30
Eligibility
Age: 16 Years and older
Sex: ALL
Volunteers: false
Enrollment: 410 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Haukeland University Hospital
Collaborators: The Research Council of Norway
Contact Information
Study Contact:
Smiti Kahlon, PhD
+4798866640
smiti.kahlon@helse-bergen.no
Tine Nordgreen, Professor
Smiti Kahlon, PhD
+47 98866640
Research Centre For Digital Mental Health Services - Haukeland University Hospital
Interventions
  • Other: Big Five — The intervention is self-guided and consists of a brief 14-page psychoeducation module that they are introduced to in the beginning of a 4-week intervention period (day 0). The module starts with a general introduction to mental health and Things you do action and how it promotes mental health. The final section presents the five core actions: 1) healthy thinking, 2) meaningful activities, 3) goals and plans, 4) healthy habits, and 5) social connections. Participants are advised to engage in the five daily actions throughout the intervention period. They are also encouraged to fill out a weekly planner and monitor their progress by keeping an overview of the number of daily activities in "My Week".The participants receive the module on a Sunday (Day 0). They receive text reminders Monday to Friday for four weeks, encouraging them to engage in the actions.
  • Other: Gratitude — The intervention is self-guided and consists of a brief 14-page psychoeducation module that they are introduced to in the beginning of a 4-week intervention period (day 0). The module starts with a general introduction to mental health and Gratitude and how it promotes mental health, followed by a short summary on the benefits of gratitude. The final section introduces practical strategies for cultivating gratitude by focusing on five key gratitude activities: 1) keeping a gratitude journal, 2) expressing gratitude to others, 3) finding gratitude in misfortune or difficult situations, 4) appreciating good things and 5) another perspective. The participants receive the module on a Sunday (Day 0). They receive text reminders Monday to Friday for four weeks, encouraging them to engage in the actions.
Study Locations (2 sites)
Research centre for digital mental health services, Bergen, Vestland 5009 Norway
Research Centre For Digital Mental Health Services - Haukeland University Hospital, Bergen, 5009 Norway
Eligibility Criteria
Inclusion Criteria: * PHQ or GAD cutoff 5 or above * Residing in Norway and have a Norwegian national identity number * 16 years or above Exclusion Criteria: * Reporting 2 or higher on PHQ item 9 (suicidality concerns) * Do not comprehend Norwegian or English
Conditions Breast Cancer, Breast Neoplasms
Phase Not Applicable
Enrollment 3300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Phase 4 of the Carolina Breast Cancer Study (CBCS4) builds on prior phases that examined molecular and epidemiologic differences in breast cancer types and outcomes. Previous findings showed that certain breast cancer subtypes and genetic factors are linked to higher risks. While prior research uncovered subtype-specific risks and relevant genetic loci, persistent disparities especially among African American (AA) and American Indian/Alaska Native (AIAN) women suggest that tumor biology alone does not fully explain outcome differences. Other important factors, like access to healthcare, treatment adherence, patient engagement must also be evaluated. In addition to collecting biological and clinical data, participants will receive a structured behavioral intervention designed to improve communication with providers and self-advocacy during cancer care. This phase includes a structured behavioral intervention designed to improve health communication and self-advocacy, both of which are hypothesized to improve health outcomes. All participants are prospectively assigned to this single-arm intervention, which includes educational resources, symptom reporting tools, reflective self-assessments, and regular engagement with trained study staff over a defined timeline. This study assesses whether structured research participation can positively influence patient behavior and ultimately reduce disparities in breast cancer care. This study also aims to better understand etiology and prognosis of breast cancer, including subtypes such as Luminal A and B, Basal-like, and Human Epidermal Growth Factor Receptor 2 positive (HER2+) / estrogen receptor negative (ER-) and to address disparities driven by both biology and systemic barriers.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Structured behavioral intervention — All participants will be prospectively assigned to a structured behavioral intervention embedded within the research process. The goal of the intervention is to improve communication with healthcare providers and enhance self-advocacy during breast cancer care. Components include reflective behavioral self-assessments, symptom reporting tools, regular interaction with nurses and lay health educators, access to webinars and newsletters, patient-centered educational materials, and the return of study results to participants through a report-back process. The behavioral engagement components are standardized and delivered over the first 12 months post-enrollment.

Primary Outcomes

  • Patient Communication Self-Efficacy Score (Baseline, 19 months, every 12-24 months up to 15 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-11-28
Completion: 2044-12-31
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 3300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: Breast Cancer Research Foundation, Susan G. Komen Breast Cancer Foundation
Contact Information
Study Contact:
Heather J Tipaldos
(919) 966-9438
heather_tipaldos@unc.edu
Melissa A Troester
(919) 966-9438
troester@email.unc.edu
Heather J Tipaldos
919-966-9438
heather_tipaldos@unc.edu
University of North Carolina at Chapel Hill
Interventions
  • Behavioral: Structured behavioral intervention — All participants will be prospectively assigned to a structured behavioral intervention embedded within the research process. The goal of the intervention is to improve communication with healthcare providers and enhance self-advocacy during breast cancer care. Components include reflective behavioral self-assessments, symptom reporting tools, regular interaction with nurses and lay health educators, access to webinars and newsletters, patient-centered educational materials, and the return of study results to participants through a report-back process. The behavioral engagement components are standardized and delivered over the first 12 months post-enrollment.
Study Locations (1 sites)
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 United States
Eligibility Criteria
Inclusion Criteria: * women with invasive breast cancer * live in 59 counties in North Carolina Exclusion Criteria: * women with ductal carcinoma in situ (DCIS) * live outside of 59 counties of North Carolina
Conditions Breast Cancer
Phase PHASE3
Enrollment 3902
Locations 138 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The advent of CDK4/6 inhibitors (drugs designed to block the action of CDK4/6 proteins, which play a key role in cell proliferation) has improved treatment prospects for patients with metastatic breast cancer whose tumour cells express hormone receptors but not the HER2 protein (HR+/HER2-). The NATALEE study showed that the addition of ribociclib for three years to conventional adjuvant hormone therapy (i.e. after surgery) prolonged survival free of invasive disease (i.e. extending to surrounding tissues) in patients with early HR breast cancer+ /HER2-. Unlike other studies, NATALEE included a group of patients at intermediate risk of recurrence, usually treated with adjuvant chemotherapy before receiving hormone therapy. However, the benefit of adjuvant chemotherapy in these patients is uncertain. The hypothesis of the NoLEEta study is that by using the CDK 4/6 inhibitor, patients could avoid adjuvant chemotherapy and therefore be spared the side-effects associated with this chemotherapy, without reducing the efficacy of the treatment.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Chemotherapy followed by endocrine therapy and ribociclib treatment — Endocrine therapy and ribociclib treatment
  • Other: De-escalation — De-escalation of the chemotherapy in the adjuvant setting

Primary Outcomes

  • Invasive breast cancer-free survival (iBCFS) (From ramdomization to iBCFS, up to 12 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-12-18
Completion: 2037-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 3902 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNICANCER
Collaborators: Novartis, SOLTI Breast Cancer Research Group, GBG Forschungs GmbH, Latin American Cooperative Oncology Group, Gruppo Italiano Mammella (GIM), BOOG Study Center, Canadian Cancer Trials Group, Swiss Cancer Institute, Menarini Silicon Biosystems, INC
Principal Investigators:
  • François-Clément BIDARD, PhD (PRINCIPAL_INVESTIGATOR) - Institut Curie
Contact Information
Study Contact:
Sandrine Marques
+33 (0) 6 17 90 00 54
s-marques@unicancer.fr
Interventions
  • Drug: Chemotherapy followed by endocrine therapy and ribociclib treatment — Endocrine therapy and ribociclib treatment
  • Other: De-escalation — De-escalation of the chemotherapy in the adjuvant setting
Study Locations (138 sites)
Clinique de l'Europe, Amiens, 80090 France
Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, 49055 France
CH Victor Dupouy, Argenteuil, 95107 France
CH Henri Mondor, Aurillac, 15000 France
Centre Hospitalier d'Auxerre, Auxerre, France
Sainte Catherine - Institut du Cancer Avignon Provence, Avignon, 84918 France
Centre Hospitalier de la Cote Basque, Bayonne, 64100 France
Centre Hospitalier Simone Veil de Beauvais, Beauvais, 60021 France
Centre Hospitalier Universitaire de Besancon, Besançon, 25000 France
Institut Bergonie, Bordeaux, 33076 France
Eligibility Criteria
Inclusion Criteria: 1. Patient must have signed a written informed consent prior to any trial-specific screening procedure. Note: When the patient is physically unable to give their written consent, an impartial witness of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent. 2. Patient is ≥ 18 years old. 3. Patient is female with known menopausal status at the time of randomization. Post-menopausal status is defined as: 1. Patient underwent bilateral oophorectomy, or 2. Age ≥ 60 years, or 3. Age \< 60 years and either amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene or ovarian suppression) or Follicle-stimulating hormone (FSH) and plasma estradiol are in the postmenopausal ranges per local normal ranges. 4. If taking tamoxifen or toremifene and age \<60 years, then FSH and plasma estradiol level in postmenopausal ranges. 4. The following criteria must be met for histologically confirmed invasive breast carcinoma, as determined by the local pathologist: 1. Pathological stage (8th edition of the AJCC), including pT2 pN0 Grade 3 or pT2 pN0 Grade 2 with Ki67≥20% or pT0-2 pN1 or pT3-4 pN0 2. ER-positive (with tumor cells showing ≥10% ER staining) and HER2-negative according to the most recent ASCO/CAP guidelines. Note: Multifocal and multicentric tumors are allowed if they meet the clinical stage II criteria of the 8th Edition of the AJCC. All tumors must be ER-positive and HER2-negative. Patients with bilateral invasive breast cancer (diagnosed simultaneously or within 6 months of each other) are eligible if all lesions tested on both sides are ER+ (ie, ≥10% positive stained cells) and HER2- AND adequate surgery has been performed in both breasts. 5. Chemotherapy eligible per investigator decision, based on clinicopathological findings or the results of any genomic signature. 6. Patient has no contraindication for the adjuvant endocrine therapy (ET) or chemotherapy in the trial and is planned to be treated with ET for 5 years (after randomization date) or more. 7. Curative surgery for the invasive disease must have been performed with negative surgical margins within 12 weeks before randomization. If positive surgical margins, patients are eligible if revision surgery or other adequate local treatment (i.e local radiotherapy) is planned. 8. Women of childbearing potential (CBP) must have a confirmed negative serum pregnancy test (β-hCG) before starting study treatment. 9. Women of childbearing potential must agree to use one effective form of contraception during trial treatment and up to 21 days after the last dose of study drugs or longer, if required per standard of care; 10. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to randomization. 11. Adequate hematological, renal, and hepatic function, as outlined below: 1. Absolute neutrophil count (ANC) ≥1.5 x 10⁹/L 2. Platelet count ≥100 x 10⁹/L 3. Hemoglobin ≥9 g/dL 4. Total bilirubin \< ULN. Patients with known Gilbert syndrome may be enrolled with total bilirubin ≤3 x ULN or direct bilirubin ≤1.5 x ULN 5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<2.5 x ULN 6. Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥60 mL/min/1.73m² (CKD-EPI equation (2021)) 7. Potassium, total calcium (corrected for serum albumin), and magnesium should be within institutional normal limits or corrected to within normal limits using supplements before the first dose of study medication. 12. Standard 12-lead ECG values assessed, as: 1. QTcF interval (QT interval using Fridericia's correction) at screening \< 450 milliseconds (msec) 2. Resting heart rate 50-100 beats per minute (determined from the ECG) 13. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures. 14. Absence of any psychological, familial or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. 15. Patients must be affiliated to a Social Security System (or equivalent) based on local regulations. Exclusion Criteria: 1. Patient has received any neoadjuvant chemotherapy since her breast cancer diagnosis or has received any prior CDK4/6 inhibitor. 2. Breast cancer diagnosed while patient was receiving tamoxifen, raloxifene or aromatase inhibitors (AIs) for reduction in risk ("chemoprevention") of breast cancer and/or treatment for osteoporosis within the last 2 years prior to randomization. 3. Patient with a known hypersensitivity to any of the excipients of ribociclib and/or ET (e.g. rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption, and soy or peanut allergy). 4. Patient with evidence or history of distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition), inflammatory breast cancer, breast cancer recurrence (local or distant) or a different primary breast cancer. 5. Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 2 years before randomization. Note: Patients with adequately treated basal or squamous cell skin carcinoma or curatively resected cervical cancer in situ are eligible. 6. Patients whose breast cancer is considered as endocrine therapy insensitive, as determined by investigator's opinion; this may include (but is not limited to) breast cancer classified as " basal like " by molecular signatures (if available in the patient file) and/or breast cancer with persistently high proliferation after pre-operative endocrine therapy. 7. Patient has had major surgery within 14 days prior to study treatment initiation. 8. Patient has known history of human immunodeficiency virus (HIV) infection (testing is not mandatory) whose antiretroviral therapy (ART) has a known strong CYP3A4 inhibitor with potential for DDI with ribociclib. Patients with HIV may be enrolled if they fulfil the criteria recommended by FDA and ASCO guidelines (FDA Guidance, Uldrick et al. 2017): 1. CD4+ T-cell (CD4+) counts ≥ 350 cells/µL, AND 2. No history of AIDS-defining opportunistic infections within the past 12 months (prophylactic antimicrobials allowed if no drug-drug interactions or overlapping toxicities), AND 3. On established ART which is not a strong CYP3A4 inhibitor, for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrolment. Effective ART is defined as a drug, dosage, and schedule associated with reduction and control of the viral load. 9. Patient has known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (testing is not mandatory). 10. Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality, including any of the following: 1. History of documented myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft within 6 months prior to trial entry. 2. Documented cardiomyopathy. 3. Left Ventricular Ejection Fraction (LVEF) \< 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) (testing not mandatory) 4. Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: * Risk factors for Torsades de Pointes (TdP) including uncorrected hypocalcemia, hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia. * Concomitant medication(s) with a known risk to prolong the QT interval and/or known to cause TdP that cannot be discontinued or replaced by safe alternative medication (e.g. within 5 half-lives or 7 days prior to starting trial treatment).